source
- Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic porphyriaDisc Medicine announced that its experimental therapy bitopertin achieved its primary and secondary goals in a Phase 3 trial for erythropoietic porphyria, a rare condition that makes patients extre…
- Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futilityArgenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…